About
Vision and strategy
Relaxera is a pharmaceutical company focused on the development of a treatment of the aging heart (Heart Failure with preserved Ejection Fraction – HFpEF), on protecting pancreatic cells against the glucotoxic effects caused by impaired glucose tolerance, and on protecting organs in the field of transplantation medicine. Our pharmaceutical candidate is relaxin-2, a member of the family of insulin-like hormones, which is released into the blood stream during partition and known for its pleiotropic effects in the human body. Relaxera has developed methods for its synthesis in large quantities and is examining its effects on the heart muscle fibres, on the islet cells of pancreas, and selected organs for transplantation.
Vision and Strategy
Relaxera Pharmazeutische Gesellschaft mbH & Co. KG (“Relaxera”) is a company dedicated to the development of pharmaceuticals and treatments with human relaxin-2 for chronic cardiovascular diseases and (pre-)diabetic conditions.
In spite of the manifold beneficial actions of relaxin-2 in cardiovascular (patho)physiology Relaxera will focus its activities on the use of synthetic human relaxin-2 for the treatment of the aging heart, heart failure with preserved ejection fraction, and the delay of the onset of type-2 diabetes in obese and overweight patients suffering from impaired glucose tolerance.
Vision and Strategy
Relaxera Pharmazeutische Gesellschaft mbH & Co. KG (“Relaxera”) is a company dedicated to the development of pharmaceuticals and treatments with human relaxin-2 for chronic cardiovascular diseases and (pre-)diabetic conditions.
In spite of the manifold beneficial actions of relaxin-2 in cardiovascular (patho)physiology Relaxera will focus its activities on the use of synthetic human relaxin-2 for the treatment of the aging heart, heart failure with preserved ejection fraction, and the delay of the onset of type-2 diabetes in obese and overweight patients suffering from impaired glucose tolerance.
Patents
Relaxera has taken all necessary actions to protect its intellectual property and ongoing developments. To date, Relaxera owns 20 patents or patent applications from 4 patent families regarding
Click here to have a look at the detailed list of patents and applications.
Patents
Relaxera has taken all necessary actions to protect its intellectual property and ongoing developments. To date, Relaxera owns 17 patents or patent applications from 3 patent families regarding
Click here to have a look at the detailed list of patents and applications.
Patents
Relaxera has taken all necessary actions to protect its intellectual property and ongoing developments. To date, Relaxera owns 17 patents or patent applications from 3 patent families regarding
Owners and advisers
CEO
Prof. Dr. Thomas Bernd Dschietzig
CEO of Relaxera, physician, specialist of Internal Medicine
Thomas Bernd Dschietzig’s research has been focused on experimental and clinical studies on the physiology and pathophysiology of human relaxin-2. His work at Charité Hospital – in the research group of Prof. Dr. Gert Baumann and Prof. Dr. Karl Stangl – led to the discovery of the endogenous expression of relaxin in human circulation and its therapeutically beneficial role in chronic human heart failure. These studies earned him the Virchow Prize of the Charité, in 2000, and the Young Investigator Award of the European Society of Cardiology, in 2001.
CO-FOUNDER
Dr. Ralf Jochem
laboratory physician
Ralf Jochem is a specialist of Laboratory Medicine. He has long since been engaged in supporting and developing innovative business concepts in medicine and laboratory diagnostics.
Prof. Dr. Wolfgang Woloszczuk
biochemist
Wolfgang Woloszczuk is the founder and former CEO of Central European Biomedica Group and now investing in biotechnology start-ups.
Dr. Franz Paul Armbruster
biochemist
Franz Paul Armbruster is founder and CEO of Immundiagnostik AG, a lab diagnostics company long since dedicated to the relaxin field.
Dr. Ulrich M. E. Benedum
biochemist, patent attorney
Ulrich Benedum graduated in biochemistry and is a patent attorney with long standing experience in medicinal, biochemical, and technical cases.
Prof. Dr. med. Wolf-Georg Forssmann
pharmacologist
Wolf-Georg Forssmann is CEO of PHARIS Biotec GmbH and one of the most renowned peptide researchers and entrepreneurs.
SCIENTIFIC ADVISORY BOARD
Clinical Advice
Prof. Dr. Stefan Anker
Advice for Cardiovascular Medicine
Berlin-Brandenburg Center for Regenerative Therapies
Charité – University Medicine Berlin, Germany
Prof. Dr. Veselin Mitrovic
Advice for Cardiovascular Medicine
Kerckhoff Clinic Forschungsgesellschaft mbH
Johann Wolfgang Goethe University Frankfurt/Main, Germany
Prof. Dr. Piotr Ponikowski
Advice for Cardiovascular Medicine
Department of Heart Diseases
Medical University, Military Hospital Wroclaw, Poland
Prof. Dr. Philipp Stiegler
Advice for Transplantation Medicine
Medical University of Graz, Austria, Departments of Transplantation Surgery and Surgical Research
Prof. Dr. Christos C. Zouboulis
Advice for Dermatology
Medical School Brandenburg, Neuruppin
Municipal Hospital Dessau, Germany
SCIENTIFIC ADVISORY BOARD
Basic Research Advice
Prof. Dr. Ross A. D. Bathgate
Co-Leader Discovery Science Theme
Florey Institute of Neuroscience and Mental Health
University of Melbourne,
Australia
Prof. Dr. Chrishan S. Samuel, BSc (Hons)
Deputy Head of Department (Research) & Head, Fibrosis Laboratory in Department of Pharmacology
Deputy Head, Cardiovascular Disease Program in Biomedicine Discovery Institute
Faculty of Medicine, Nursing & Health Sciences
Monash University, Clayton – Victoria, Australia
Prof. Dr. M. Akhter Hossain
Head, Insulin Peptides Laboratory
Florey Institute of Neuroscience and Mental Health
University of Melbourne,
Australia